Li CH, Chen ZM, Chen PF, Meng L, Sui WN, Ying SC, Xu AM, Han WX. Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells. World J Gastrointest Oncol 2022; 14(10): 1968-1980 [PMID: 36310707 DOI: 10.4251/wjgo.v14.i10.1968]
Corresponding Author of This Article
Wen-Xiu Han, MD, PhD, Professor, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Avenue, Shushan District, Hefei 230022, Anhui Province, China. hwxhbh@126.com
Research Domain of This Article
Oncology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Li CH, Chen ZM, Chen PF, Meng L, Sui WN, Ying SC, Xu AM, Han WX. Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells. World J Gastrointest Oncol 2022; 14(10): 1968-1980 [PMID: 36310707 DOI: 10.4251/wjgo.v14.i10.1968]
World J Gastrointest Oncol. Oct 15, 2022; 14(10): 1968-1980 Published online Oct 15, 2022. doi: 10.4251/wjgo.v14.i10.1968
Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells
Chuan-Hong Li, Zhang-Ming Chen, Pei-Feng Chen, Lei Meng, Wan-Nian Sui, Song-Cheng Ying, A-Man Xu, Wen-Xiu Han
Chuan-Hong Li, Zhang-Ming Chen, Pei-Feng Chen, Lei Meng, Wan-Nian Sui, A-Man Xu, Wen-Xiu Han, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China
Song-Cheng Ying, Department of Immunology, College of Basic Medicine, Anhui Medical University, Hefei 230022, Anhui Province, China
Author contributions: Li CH, Chen ZM, and Chen PF collected the data and wrote the manuscript; Sui WN participated in data analysis; Ying SC participated in discussion and language editing; Xu AM provided funding support; Han WX reviewed the manuscript and provided funding support; All authors contributed to the article and approved the submitted version.
Supported bythe Natural Science Project of Anhui Province, No. KJ2021ZD0022; and the Key Research and Development Program of Anhui Province, No. 202104J07020029.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of The First Affiliated Hospital of Anhui Medical University (Quick PJ 2019-09-01).
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Anhui Medical University (SC20200513).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There is no conflict of interest in this study.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at email address hwxhbh@126.com. Participants gave informed consent for data sharing.
ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.
Corresponding author: Wen-Xiu Han, MD, PhD, Professor, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Avenue, Shushan District, Hefei 230022, Anhui Province, China. hwxhbh@126.com
Received: May 30, 2022 Peer-review started: May 30, 2022 First decision: June 21, 2022 Revised: July 4, 2022 Accepted: August 21, 2022 Article in press: August 21, 2022 Published online: October 15, 2022 Processing time: 136 Days and 22 Hours
ARTICLE HIGHLIGHTS
Research background
Interleukin (IL)-34 is an inflammatory cytokine that is also involved in the development of several tumors. However, the role of IL-34 in the proliferation and epithelial-mesenchymal transition (EMT) of gastric cancer (GC) remains to be investigated.
Research motivation
To investigate the effect of IL-34 on the proliferation of GC cells and to find new therapeutic targets for the treatment of GC.
Research objectives
To clarify the effect of IL-34 on the prognosis of GC patients and the effect of IL-34 on the proliferation and EMT of GC cells.
Research methods
The expression of IL-34 protein in GC tissues and cells was detected using immunohistochemical staining and Western blotting. In vitro, stable IL-34 knockdown and overexpressed GC cell lines were cultured, and the proliferation, clone formation, migration and invasion ability of GC cells were examined using cholecystokinin-8 assay, clone formation assay, cell scratch assay and transwell assay, respectively. In vivo, the effect of IL-34 on GC transplantation tumor growth was assessed using a subcutaneous tumor transplantation assay in nude mice. Western blotting was used to detect the association of IL-34 protein with EMT-related protein expression levels.
Research results
IL-34 expression is elevated in GC cells and tissues, and IL-34 expression levels correlated with tumor size, T stage, N stage, tumor, node and metastasis stage, and degree of differentiation. In vitro, endogenous upregulation of IL-34 promoted GC cell proliferation and EMT. In vivo, IL-34 overexpression promoted subcutaneous graft tumor growth in nude mice.
Research conclusions
IL-34 expression is increased in GC tissues and cell lines. IL-34 promotes the proliferation and epithelial-mesenchymal transition of GC cells.
Research perspectives
IL-34 may represent a new strategy for the diagnosis and targeted treatment of GC. Further search for potential cancer-promoting mechanisms of IL-34 is needed in the future.
